Author: Andrew Cass

The CMS decision to limit coverage of a controversial new Alzheimer's drug was a "triumph of the scientific process," Arthur Caplan, PhD, who directs the medical ethics division of NYU Grossman's School of Medicine, said in an April 10 Washington…

States will need to review the eligibility of millions of people enrolled in Medicaid once the COVID-19 public health emergency expires. 

The U.S. House of Representatives passed a bill March 31 that would cap the out-of-pocket cost for insulin at $35, and the Senate is working on legislation of its own, according to Kaiser Health News.

The public's top healthcare priorities for Congress involve limiting drug prices, according to a Kaiser Family Foundation poll published March 31. 

The White House announced April 4 that more than 59 million Americans with Medicare Part B, including those enrolled in a Medicare Advantage plan, can now receive free over-the-counter COVID-19 tests. 

Here are five recent lawsuits and settlements involving payers: 

Proposed legislation making its way through Congress that would cap the out-of-pocket cost for insulin at $35 would do nothing to lower the price of insulin, according to health insurer lobby and trade group America's Health Insurance Plans. 

The Government Accountability Office found that consumers face a variety of challenges accessing mental health benefits provided under their health plans, according to a March 30 report. 

UnitedHealthcare has agreed to pay a $100,000 fine after the Rhode Island health insurance commissioner's office found that the payer did not follow state law when it denied substance use disorder treatment claims. 

Ten providers — including the University of Maryland Medical Center, Penn Medicine and North Kansas City Hospital — recently posted job listings seeking leaders in payer contracting and relations.